These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 19519692)

  • 1. Extremely low doses of lepirudin in a patient with heparin-induced thrombocytopenia, high bleeding risk and renal insufficiency.
    Tardy-Poncet B; Charier D; Diconne E; Zeni F; Garraud O; Tardy B; Campos L
    Br J Haematol; 2009 Aug; 146(4):456-7. PubMed ID: 19519692
    [No Abstract]   [Full Text] [Related]  

  • 2. Recommended and actual lepirudin doses in patients with renal insufficiency.
    Saxer SB; Smith BS; Gandhi PJ; Tataronis GR; Krikorian SA
    Am J Health Syst Pharm; 2003 Dec; 60(24):2588-93. PubMed ID: 14735776
    [No Abstract]   [Full Text] [Related]  

  • 3. Lepirudin in the management of heparin-induced thrombocytopenia.
    Gajra A; Husain J; Smith A
    Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1131-41. PubMed ID: 18680447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia.
    Kiser TH; Jung R; MacLaren R; Fish DN
    Pharmacotherapy; 2005 Dec; 25(12):1736-45. PubMed ID: 16305293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients.
    Tschudi M; Lämmle B; Alberio L
    Blood; 2009 Mar; 113(11):2402-9. PubMed ID: 19059879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous lepirudin for heparin-induced thrombocytopenia and when other anticoagulants fail: illustrative cases.
    Deitcher SR; Ngengwe R; Kaplan R; Liebman H; Kaplan K; Blinder M
    Clin Adv Hematol Oncol; 2004 Jun; 2(6):382-4; discussion 384-6. PubMed ID: 16163209
    [No Abstract]   [Full Text] [Related]  

  • 7. Prolonged half-life of argatroban in patients with renal dysfunction and antiphospholipid antibody syndrome being treated for heparin-induced thrombocytopenia.
    Athar U; Husain J; Hudson J; Lynch J; Gajra A
    Am J Hematol; 2008 Mar; 83(3):245-6. PubMed ID: 17910040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
    Pinto DS; Sperling RT; Tu TM; Cohen DJ; Carrozza JP
    Catheter Cardiovasc Interv; 2003 Jan; 58(1):65-8. PubMed ID: 12508198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of lepirudin in patients with heparin-induced thrombocytopenia and renal failure requiring hemodialysis.
    Dager WE; White RH
    Ann Pharmacother; 2001; 35(7-8):885-90. PubMed ID: 11485140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bilateral renal artery thrombosis due to heparin-induced thrombocytopenia-thrombosis syndrome. Successful treatment with longterm application of lepirudin.
    Tsirigotis P; Mantzios G; Makris F; Robos Y
    Ulster Med J; 2006 Jan; 75(1):88-90. PubMed ID: 16457411
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of heparin-induced thrombocytopenia: is there a role for bivalirudin?
    Seybert AL; Coons JC; Zerumsky K
    Pharmacotherapy; 2006 Feb; 26(2):229-41. PubMed ID: 16466327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A case of heparin induced thrombocytopenia treated with lepirudin infusion: case report].
    Sünmez S; Okumuş G; Kiyan E; Ece T; Arseven O
    Tuberk Toraks; 2006; 54(2):185-8. PubMed ID: 16924578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia.
    Kiser TH; Burch JC; Klem PM; Hassell KL
    Pharmacotherapy; 2008 Sep; 28(9):1115-24. PubMed ID: 18752382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical challenge: heparin-induced thrombocytopenia type II (HIT II) or pseudo-HIT in a patient with antiphospholipid syndrome.
    Perunicic J; Antonijevic NM; Miljic P; Djordjevic V; Mikovic D; Kovac M; Djokic M; Mrdovic I; Nikolic A; Vasiljevic Z
    J Thromb Thrombolysis; 2008 Oct; 26(2):142-6. PubMed ID: 17828468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of lepirudin in haemodialysis complicated with heparin-induced thrombocytopenia type II (HIT II)--dosage monitoring.
    Kassimatis TI; Apostolou T; Theodoridis T; El Ali M; Hadjiconstantinou V
    Nephrol Dial Transplant; 2006 Nov; 21(11):3341-2. PubMed ID: 16822790
    [No Abstract]   [Full Text] [Related]  

  • 16. Management of lepirudin therapy for a patient with antiphospholipid antibody syndrome using the whole blood ecarin clot time and activated partial thromboplastin time.
    Perry SL; O'Shea SI; Ortel TL
    Blood Coagul Fibrinolysis; 2003 Sep; 14(6):601-4. PubMed ID: 12960616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term application of lepirudin on chronic haemodialysis over 34 months after heparin-induced thrombocytopenia.
    Gay BE; Räz HR; Schmid HR; Beer JH
    Nephrol Dial Transplant; 2007 Jun; 22(6):1790-1. PubMed ID: 17395662
    [No Abstract]   [Full Text] [Related]  

  • 18. Lepirudin anticoagulation for heparin-induced thrombocytopenia.
    Deitcher SR; Topoulos AP; Bartholomew JR; Kichuk-Chrisant MR
    J Pediatr; 2002 Feb; 140(2):264-6. PubMed ID: 11865285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lepirudin for heparin-induced thrombocytopenia.
    Med Lett Drugs Ther; 1998 Sep; 40(1036):94-5. PubMed ID: 9774965
    [No Abstract]   [Full Text] [Related]  

  • 20. Bivalirudin anticoagulation for a patient with hypercoagulable immune syndromes undergoing mitral valve surgery.
    Cain RL; Spiess BD; Nelson M; Deanda A; McCarthy HL; Green JA
    Ann Thorac Surg; 2006 Jun; 81(6):2308-10. PubMed ID: 16731183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.